Citations

Showing 10 of 108083 citations.

Thoracic Radiology: Recent Developments and Future Trends
McLoud, Theresa C. , Little, Brent P. , Little, Brent P

Mayo Clinic

Radiology | January 17, 2023 | Volume: 306 | Issue: 2 | Pages: No page available

10.1148/radiol.223121 | PMID 36648345 Get It

Management of Trigeminal Autonomic Cephalalgias Including Chronic Cluster
Tassorelli, Cristina , Diener, Hans‐Christoph , Dodick, David W.

Mayo Clinic

JAMA Neurology | January 17, 2023 | Volume: 80 | Issue: 3 | Pages: 308

10.1001/jamaneurol.2022.4804 | PMID 36648786 Get It

Importance Trigeminal autonomic cephalalgias (TACs) comprise a unique collection of primary headache disorders characterized by moderate or severe unilateral pain, localized in in the area of distribution of the first branch of the trigeminal nerve, accompanied by cranial autonomic symptoms and signs. Most TACs are rare diseases, which hampers the possibility of performing randomized clinical trials and large studies. Therefore, knowledge of treatment efficacy must be based only on observational studies, rare disease registries, and case reports, where real-world data and evidence play an important role in health care decisions. Observations Chronic cluster headache is the most common of these disorders, and the literature offers some evidence from randomized clinical trials to support the use of pharmacologic and neurostimulation treatments. Galcanezumab, a monoclonal antibody targeting the calcitonin gene-related peptide, was not effective at 3 months in a randomized clinical trial but showed efficacy at 12 months in a large case series. For the other TACs (ie, paroxysmal hemicrania, hemicrania continua, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing, and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms), only case reports and case series are available to guide physicians in everyday management. Conclusions and Relevance The accumulation of epidemiologic, pathophysiologic, natural history knowledge, and data from case series and small controlled trials, especially over the past 20 years from investigators around the world, has added to the previously limited evidence and has helped advance and inform the treatment approach to rare TACs, which can be extremely challenging for clinicians.
Inflation reduction act: Would it impact Medicare’s spending on anti-VEGF drugs in ophthalmology?
Sheng, Young, Stewart, Michael W., Narayanan, Raja

Mayo Clinic

IHOPE Journal of Ophthalmology | January 17, 2023 | Volume: 2 | Issue: No issue available | Pages: 1-3

10.25259/ihopejo_37_2022 Get It

Adequacy of cefepime concentrations in the early phase of critical illness: A case for precision pharmacotherapy
Frazee, Erin N. , Chang, Jack , Bjergum, Matthew W., Gajić, Ognjen, Jannetto, Paul J. , Mara, Kristin C. , Meade, Laurie A., Vollmer, Kathryn J., Scheetz, Marc H. , Group, For the BLOOM Study, Frazee, Erin N , Scheetz, Marc H , Mara, Kristin C , Gajic, Ognjen , Rule, Andrew D. , Group, For the BLOOM Study

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | January 17, 2023 | Volume: 43 | Issue: 11 | Pages: 1112-1120

10.1002/phar.2766 | PMID 36648390 Get It

AbstractStudy ObjectiveIn critically ill patients, adequacy of early antibiotic exposure has been incompletely evaluated. This study characterized factors associated with inadequate cefepime exposure in the first 24 h of critical illness.DesignProspective cohort study.SettingAcademic Medical Center.PatientsCritically ill adults treated with cefepime. Patients with acute kidney injury or treated with kidney replacement therapy or extracorporeal membrane oxygenation were excluded.InterventionNone.MeasurementsA nonlinear mixed‐effects pharmacokinetic (PK) model was developed to estimate cefepime concentrations for each patient over time. The percentage of time the free drug concentration exceeded 8 mg/L during the first 24 h of therapy was calculated (%ƒT>8; appropriate for the susceptible breakpoint for Pseudomonas aeruginosa). Factors predictive of low %ƒT>8 were explored with multivariable regression.Main ResultsIn the 100 included patients, a one‐compartment PK model was developed with first‐order elimination with covariates for weight and estimated glomerular filtration rate based on creatinine and cystatin C (eGFRSCr‐CysC). The median (interquartile range) %ƒT>8 for cefepime in the first 24 h of therapy based on this model was 85% (66%, 100%). Less than 100% ƒT>8 during first 24 h of therapy occurred in 70 (70%) individuals. Lower Sequential Organ Failure Assessment score (p = 0.032) and higher eGFRSCr‐CysC (p < 0.001) predicted a lower %ƒT>8. Central nervous system infection source was protective (i.e., associated with a higher %ƒT>8; p = 0.008).ConclusionsDuring early critical illness, cefepime concentrations were inadequate in a significant proportion of patients. Antimicrobial optimization is needed to improve the precision of pharmacotherapy in the critically ill patients.
Setting the Standard for Cutaneous Melanoma Wide Local Excision: An Overview of the American College of Surgeons Commission on Cancer Standard 5.5
Lillemoe, Heather A. , Williams, Jelani K., Teshome, Mediget , Zheng, Linda , Francescatti, Amanda B. , Katz, Matthew H. G. , Hunt, Kelly, Vreeland, Timothy J. , Asare, Elliot A. , Katz, Matthew H G , Hieken, Tina J.

Mayo Clinic

Journal of the American College of Surgeons | January 17, 2023 | Volume: 236 | Issue: 2 | Pages: 424-428

10.1097/xcs.0000000000000481 | PMID 36648270 Get It

The purpose of this article is to review the objectives of the American College of Surgeons Commission on Cancer Operative Standards with a specific focus on Standard 5.5, which pertains to curative intent wide local excision of primary cutaneous melanoma lesions. We review the details and rationale of the standard itself, including its requirement to include specific elements and responses in synoptic format in operative reports.
A New Index of Insulin Sensitivity from Glucose Sensor and Insulin Pump Data: In Silico and In Vivo Validation in Youths with Type 1 Diabetes
Schiavon, Michele , Galderisi, Alfonso , Basu, Ananda , Kudva, Yogish C. , Man, Chiara Dalla , Dalla Man, Chiara , Schiavon, Michele , Cengiz, Eda

Mayo Clinic

Diabetes Technology & Therapeutics | January 17, 2023 | Volume: 25 | Issue: 4 | Pages: 270-278

10.1089/dia.2022.0397 | PMID 36648253 Get It

Background: Estimation of insulin sensitivity (S I ) and its daily variation are key for optimizing insulin therapy in patients with type 1 diabetes (T1D). We recently developed a method for S I estimation from continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII) data in adults with T1D (S I SP ) and validated it under restrained experimental conditions. Herein, we validate in vivo a new version of S I SP performing well in daily life unrestrained conditions. Methods: The new S I SP was tested in both simulated and real data. The simulated dataset consists of 100 virtual adults of the UVa/Padova T1D Simulator monitored during an open-loop experiment, whereas the real dataset consists of 10 youths with T1D monitored during a hybrid closed-loop meal study. In both datasets, participants underwent two consecutive meals (breakfast and lunch, at 7 and 11 am) with the same carbohydrate content (70 g). Plasma glucose and insulin were measured during each meal to estimate the oral glucose minimal model S I (S I MM ). CGM and CSII data were used for S I SP calculation, which was then validated against the gold standard S I MM . Results: S I SP was estimated with good precision (median coefficient of variation <20%) in 100% of the real and 91% of the simulated meals. S I SP and S I MM were highly correlated, both in the simulated and real datasets ( R = 0.82 and R = 0.83, P < 0.001), and exhibited a similar intraday pattern. Conclusions: S I SP is suitable for estimating S I in both closed- and open-loop settings, provided that the subject wears a CGM sensor and a subcutaneous insulin pump.
Knee immobilization reproduces key arthrofibrotic phenotypes in mice
Dagneaux, Louis , Limberg, Afton K. , Owen, Aaron R. , Bettencourt, Jacob W. , Dudakovic, Amel , Bayram, Banu , Gades, Naomi M. , Berry, Daniel J., Berry, Daniel J. , Sanchez-Sotelo, Joaquin, van Wijnen, Andre, Berry, Daniel J , Sánchez‐Sotelo, Joaquín , Berry, Daniel J., Wijnen, André J. van , Morrey, Mark E. , Abdel, Matthew P.

Mayo Clinic

Bone & Joint Research | January 17, 2023 | Volume: 12 | Issue: 1 | Pages: 58-71

10.1302/2046-3758.121.bjr-2022-0250.r2 | PMID 36647696 Get It

Aims As has been shown in larger animal models, knee immobilization can lead to arthrofibrotic phenotypes. Our study included 168 C57BL/6J female mice, with 24 serving as controls, and 144 undergoing a knee procedure to induce a contracture without osteoarthritis (OA). Methods Experimental knees were immobilized for either four weeks (72 mice) or eight weeks (72 mice), followed by a remobilization period of zero weeks (24 mice), two weeks (24 mice), or four weeks (24 mice) after suture removal. Half of the experimental knees also received an intra-articular injury. Biomechanical data were collected to measure passive extension angle (PEA). Histological data measuring area and thickness of posterior and anterior knee capsules were collected from knee sections. Results Experimental knees immobilized for four weeks demonstrated mean PEAs of 141°, 72°, and 79° after zero, two, and four weeks of remobilization (n = 6 per group), respectively. Experimental knees demonstrated reduced PEAs after two weeks (p < 0.001) and four weeks (p < 0.0001) of remobilization compared to controls. Following eight weeks of immobilization, experimental knees exhibited mean PEAs of 82°, 73°, and 72° after zero, two, and four weeks of remobilization, respectively. Histological analysis demonstrated no cartilage degeneration. Similar trends in biomechanical and histological properties were observed when intra-articular violation was introduced. Conclusion This study established a novel mouse model of robust knee contracture without evidence of OA. This was appreciated consistently after eight weeks of immobilization and was irrespective of length of remobilization. As such, this arthrofibrotic model provides opportunities to investigate molecular pathways and therapeutic strategies. Cite this article: Bone Joint Res 2023;12(1):58–71.
“There's not enough studies”: Views of black breast and ovarian cancer patients on research participation
Riggan, Kirsten A. , Rousseau, Abigail , Halyard, Michele Y. , James, Sarah E. , Kelly, Marion, Phillips, Daphne, Allyse, Megan , Halyard, Michele , Allyse, Megan A , Rousseau, Abigail C , Riggan, Kirsten A , Phillips, Daphne

Mayo Clinic

Cancer Medicine | January 17, 2023 | Volume: 12 | Issue: 7 | Pages: 8767-8776

10.1002/cam4.5622 | PMID 36647342 Get It

AbstractBackgroundBlack breast and ovarian cancer patients are underrepresented in clinical cancer trials disproportionate to the prevalence of these cancers in Black females. Historically, lower enrollment has been attributed to individualized factors, including medical mistrust, but more recently structural factors, including systemic racism, have received additional scrutiny. We interviewed Black women with a personal or family history of breast and ovarian cancer to understand their views and experiences related to research participation.MethodsQualitative interviews were conducted via telephone or video conference and transcribed verbatim. Transcripts were qualitatively analyzed for iterative themes related to the offer and participation in cancer clinical trials and research studies, impact on cancer care, and recommendations to increase enrollment of Black patients.ResultsSixty‐one Black women completed an interview. Participants expressed that Black women are underrepresented in cancer research, and that this negatively impacted their own care. Many cited past historical abuses, including the Tuskegee syphilis trial, as a potential factor for lower enrollment but suggested that lower enrollment was better understood in the context of the entirety of their healthcare experiences, including present‐day examples of patient mistreatment or dismissal. Participants suggested that proactive community engagement, transparency, and increased representation of Black research team members were strategies likely to foster trust and bolster research participation.Conclusion(s)Medical mistrust is only a partial factor in the lower participation of Black patients in cancer research. Researchers should implement the strategies identified by our participants to promote diverse enrollment and ensure that Black patients are included in future therapeutic advances.
Impact of an Acquisition Advanced Practice Provider on Home Hospital Patient Volumes and Length of Stay
Felix, Heidi, Cowdell, Jed C. , Maita, Karla C. , Dugani, Sagar B. , Matcha, Gautam , Maniaci, Michael J. , Felix, Heidi M, Paulson, Margaret R. , Dugani, Sagar B , Torres-Guzman, Ricardo A, Matcha, Gautam V , Maniaci, Michael J , Felix, Heidi M., Ávila, Francisco R. , Torres‐Guzman, Ricardo A. , Forte, Antonio J.

Mayo Clinic

Healthcare | January 17, 2023 | Volume: 11 | Issue: 3 | Pages: 282

10.3390/healthcare11030282 | PMID 36766857 Get It

In July 2020, Mayo Clinic introduced a hospital-at-home program, known as Advanced Care at Home (ACH) as an alternate option for clinically stable medical patients requiring hospital-level care. This retrospective cohort study evaluates the impact of the addition of a dedicated ACH patient acquisition Advanced Practice Provider (APP) on average length of stay (ALOS) and the number of patients admitted into the program between in Florida and Wisconsin between 6 July 2020 and 31 January 2022. Patient volumes and ALOS of 755 patients were analyzed between the two sites both before and after a dedicated acquisition APP was added to the Florida site on 1 June 2021. The addition of a dedicated acquisition APP did not affect the length of time a patient was in the emergency department or hospital ward prior to ACH transition (2.91 days [Florida] vs. 2.59 days [Wisconsin], p = 0.22), the transition time between initiation of the ACH consult to patient transfer home (0.85 days [Florida] vs. 1.16 days [Wisconsin], p = 0.28), or the total ALOS (6.63 days [Florida] vs. 6.34 days [Wisconsin], p = 0.47). The average number of patients acquired monthly was significantly increased in Florida (38.3 patients per month) compared with Wisconsin (21.6 patients per month) (p < 0.01). The addition of a dedicated patient acquisition APP resulted in significantly higher patient volumes but did not affect transition time or ALOS. Other hospital-at-home programs may consider the addition of an acquisition APP to maximize patient volumes.
GFR estimated with creatinine rather than cystatin C is more reflective of the true risk of adverse outcomes with low GFR in kidney transplant recipients
Keddis, Mira T. , Howard, Matthew R., Galapia, Leyton, Frazee, Erin N. , Zhang, Nan , Butterfield, Richard , Rule, Andrew D.

Mayo Clinic

Nephrology Dialysis Transplantation | January 17, 2023 | Volume: 38 | Issue: 8 | Pages: 1898-1906

10.1093/ndt/gfad007 | PMID 36646435 Get It

ABSTRACT Background Serum cystatin C–based estimated glomerular filtration rate (eGFRcys) generally associates with clinical outcomes better than serum creatinine–based eGFR (eGFRcr) despite similar precision in estimating measured GFR (mGFR). We sought to determine whether the risk of adverse outcomes with eGFRcr or eGFRcys was via GFR alone or also via non-GFR determinants among kidney transplant recipients. Methods Consecutive adult kidney transplant recipients underwent a standardized GFR assessment during a routine follow-up clinic visit between 2011 and 2013. Patients were followed for graft failure or the composite outcome of cardiovascular (CV) events or mortality through 2020. The risk of these events by baseline mGFR, eGFRcr and eGFRcys was assessed unadjusted, adjusted for mGFR and adjusted for CV risk factors. Results There were 1135 recipients with a mean baseline mGFR of 55.6, eGFRcr of 54.8 and eGFRcys of 46.8 ml/min/1.73 m2 and a median follow-up of 6 years. Each 10 ml/min/1.73 m2 decrease in mGFR, eGFRcr or eGFRcys associated with graft failure [hazard ratio (HR) 1.79, 1.68 and 2.07, respectively; P &lt; .001 for all) and CV events or mortality outcome (HR 1.28, 1.19 and 1.43, respectively; P &lt; .001 for all). After adjusting for mGFR, eGFRcys associated with graft failure (HR 1.57, P &lt; .001) and CV events or mortality (HR 1.49, P &lt; .001), but eGFRcr did not associate with either. After further adjusting for CV risk factors, risk of these outcomes with lower eGFRcys was attenuated. Conclusion eGFRcr better represents the true relationship between GFR and outcomes after kidney transplantation because it has less non-GFR residual association. Cystatin C is better interpreted as a nonspecific prognostic biomarker than is eGFR in the kidney transplant setting.